42 results about "Sinus inflammation" patented technology

Provided herein are methods and uses of antibodies that specifically bind human IL-13 ("anti-IL-13 antibodies") for the treatment of chronic rhinosinusitis with nasal polyps.

The present invention relates to an antisense oligonucleotide targeting an interleukin 4 receptor and the use thereof. The antisense oligonucleotide (ASO) molecule has a length of 16-22 bases and is specifically paired with a specific region of a target gene (interleukin 4 receptor). The ASO is used for treating diseases associated with IL-4Rα, which includes, but is not limited to, asthma (including eosinophilic asthma), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, prurigo nodularis, urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, pruritus, and gastritis.

The present invention discloses a novel stable, single phase aqueous suspension for nasal administration to treat bacterial sinusitis. The composition takes azithromycin dihydrate as an active ingredient, and adopts a suspending agent system to prevent phase separation during storage. Embodiments include a formulation comprising a sorbitan monolaurate, or a combination of chitosan and a sorbitan monolaurate, to maintain the stability of the suspension. The present invention has a variety of advantages, including local delivery of azithromycin to an infected site, which can reduce systemic exposure and associated side effects compared to oral formulations.

The invention belongs to the technical field of biological medicines, and relates to an efficient affinity anti-human IL-33 monoclonal antibody and a preparation method thereof. The monoclonal antibody provided by the invention has good specificity and affinity, accurately targets a key cell factor IL-33, and effectively blocks a binding path between the key cell factor IL-33 and a receptor ST2. As a core factor mediating various inflammatory diseases, such as asthma, allergic dermatitis, chronic sinusitis, chronic obstructive pulmonary disease (COPD) and the like, IL-33 is crucial in intervention of a regulation mechanism for disease treatment. The monoclonal antibody disclosed by the invention is novel in sequence, and provides a new thought for preparation of the medicine by inhibiting IL-33 mediated inflammatory reaction.

The invention provides a budesonide temperature-sensitive gel preparation as well as a preparation method and application thereof, and the budesonide temperature-sensitive gel preparation is mainly prepared from the following components: budesonide, poloxamer 407, poloxamer 188, propylene glycol, hydroxypropyl methyl cellulose, sodium benzoate and pure water. After the budesonide temperature-sensitive gel drug delivery system based on poloxamer 407, poloxamer 188 and hydroxypropyl methylcellulose is applied to a cavity, semi-solid gel can be quickly formed, and strong retention and slow release effects are shown, so that the bioavailability is increased, the formed semi-solid gel can be retained at a drug delivery part and cannot be lost, and the budesonide temperature-sensitive gel drug delivery system is suitable for clinical application. In addition, budesonide can be gradually released, and a remarkable curative effect is shown in short-term clinical application of recurrent chronic sinusitis with nasal polyp.

The present application relates to treatment of nasal cavity inflammation and mucus hypersecretion. One aspect of the present invention is a method of treatment of rhinitis and rhinosinusitis, wherein the treatment reduces nasal stuffiness, nasal congestion, and phlegm secretion. Reduction of phlegm secretion from the nasal cavity into the pharynx can also reduce cough frequency from infectious and allergic rhinitis. In the preferred embodiment, FEMA 4557, is an example of a molecule, topically applied to the nasal mucosa, that can be used to treat rhinitis. FEMA 4557 is a potent non-irritating suppressor of acute inflammation in the nasal cavity and sinuses, a property not previously described for other topical cooling agents. Thus, FEMA 4557 and related analogs may have therapeutic utility for treating nasal inflammation and mucus hypersecretion.

Disclosed herein are antigen binding proteins, e.g. an antibody, which bind to IL-5, for use in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), wherein the nasal polyps score and / or mean nasal obstruction score is improved.

A composition comprising isolated Streptococcus pyogenes extracellular vesicles (EVs) suspended in a vehicle, for use in eliciting an adaptive immune response against group A streptococcus (GAS) in a subject. The EVs may comprise antigens MtsA, Spy_1228, PrsA1, PrsA2, SPy_0319 and / or GlnP. A composition comprising isolated S. pyogenes protein(s) MtsA, SPy_1228, PrsA1, PrsA2, GlnP, SPy_0319 and / or MalX. The compositions may be used for inducing protective immunity in a subject against a GAS infection, such as streptococcal pharyngitis, scarlet fever, impetigo, streptococcal meningitis, streptococcal sinusitis, necrotizing fasciitis, cellulitis, streptococcal toxic shock syndrome, rheumatic fever and post-streptococcal glomerulonephritis.

Disclosed are compositions and methods for treating, amelioriating, reversing and / or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and / or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.

A method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, the method comprising administering 150 mg / mL omalizumab formulation, wherein the omalizumab is administered subcutaneously by a syringe.

Contemplated compositions and methods employ betalains for treatment of various conditions, and especially osteoarthritis, sinusitis, contact dermatitis, acne, an allergic condition, reduced mental alertness, reduced physical strength, reduced physical endurance, and / or impaired mood.

The invention provides an eCRSwNP nasal endoscopic postoperative treatment method for regulating acidophilic granulocyte activity based on acupuncture, and relates to the technical field of traditional Chinese medicine for preventing and treating nasosinusitis diseases. According to the eCRSwNP nasal endoscopic post-operation treatment method for adjusting the acidophilic granulocyte activity based on acupuncture, accurate adjustment of the acidophilic granulocyte activity is achieved through a synergistic scheme of a nasal endoscopic operation, perioperative drug treatment and standardized acupuncture treatment, the postoperative recurrence rate is reduced, and the nasal symptom and life quality of a patient are improved. Acupuncture point selection, operation specifications, treatment frequency and treatment course of acupuncture are defined, a repeatable and generalizable standardized treatment scheme is formed in combination with strict patient screening standards, a quality control system and ethical guarantee, the technical problems that existing eCRSwNP postoperative treatment is lack of targeted immunoregulation means and the recurrence rate is high are solved, and the therapeutic effect of the eCRSwNP postoperative treatment is improved. And a new clinical path is provided for traditional Chinese medicine intervention on refractory nasosinusitis diseases.

The invention relates to a herbal preparation in the form of film-coated tablets for the supportive treatment of allergic rhinitis and sinusitis, and a process for preparing such a preparation. The preparation according to the invention contains herbal extracts obtained from a mixture of medicinal herbs including Bupleurum root (Radix Bupleurum), Platycodon grandiflorus root (Radix Platycodi grandiflori), Xanthium strumarium fruit (Fructus Xanthii strumarii), Magnolia officinalis flower (Flos Magnoliae), and Oroxylum indicum bark (Cortex Oroxyli indici), in which each herb is used in appropriate amounts to create synergistic anti-inflammatory, anti-allergic, decongestant, expectorant, and immune-enhancing effects on the respiratory mucosa. The preparation also includes a film-coating system containing a film-forming polymer, plasticizer, and coloring agent, along with tablet-forming excipients such as preservatives, fillers, stabilizers, and anti-caking agents in appropriate proportions to create a highly stable film-coated tablet.The preparation according to the invention has the advantages of preserving the active ingredients of the medicinal herbs, increasing stability, improving bioavailability, being convenient to use, and contributing to enhancing the effectiveness of supporting the treatment of symptoms of allergic rhinitis and sinusitis. It is also safe for long-term use because the preparation contains herbal extracts of natural origin that have been used for a long time in traditional medicine, and does not contain synthetic vasoconstrictors, corticosteroids, or antibiotics. In addition, the extraction and purification process helps remove impurities and reduce irritating components, thereby limiting the risk of unwanted side effects with prolonged use.

The invention belongs to the technical field of biological medicines, and relates to a monoclonal antibody capable of being specifically combined with IL-33 as well as a preparation method and application thereof. The monoclonal antibody capable of being specifically bound with the IL-33 can be specifically bound with the IL-33 in a high-affinity mode, and therefore binding of the IL-33 and a receptor ST2 of the IL-33 is effectively blocked. IL-33 is an important cell factor, and plays a key role in the occurrence and development of various diseases, such as asthma, specific reactive / allergic dermatitis, chronic sinusitis, chronic obstructive pulmonary disease (COPD) and the like. By blocking the combination of IL-33 and ST2, the antibody can inhibit inflammatory reactions mediated by IL-33, and a new strategy is provided for the treatment of these diseases.

The invention discloses a medicinal moxa composition for preventing and treating chronic nasosinusitis and kidney stone co-disease. The medicinal moxa composition comprises asarum, gardenia jasminoides, agilawood and moxa. The medicinal moxa composition disclosed by the invention generates an external preparation with synergistic effects of smoke, medicinal gas and heating power through combustion. Volatile components of the four medicines are burnt to form a composite pharmacodynamic system which is absorbed by skin, mucous membrane and respiratory system to generate a unique treatment effect. The medicinal moxa composition can realize cold-warm balance, multi-target coordination, immunoregulation, anti-inflammatory action and diuresis metabolism regulation through the synergistic effect of heating power and volatile matters, so that the dual effects of preventing and treating nasosinusitis and kidney stone are achieved. Due to the external use characteristic, the traditional Chinese medicine composition can directly act on body surface acupuncture points and is conducted to related viscera through meridians and collaterals to form a treatment path from the outside to the inside.

This invention belongs to the field of nanomedicine delivery and immunotherapy technology, and provides a treatment for CD4-positive conditions including asthma, inflammatory bowel disease, and chronic sinusitis. + A CD4-targeting Runx3-siRNA nanodelivery system for T-cell-mediated chronic inflammatory diseases comprises lipid nanoparticles loaded with Runx3-siRNA and a CD4-targeting ligand coupled to the surface of the lipid nanoparticles. This system enables targeting of pathogenic CD4-mediated chronic inflammatory diseases. + T-cell-specific delivery and Runx3 gene silencing; lipid nanoparticles composed of ionic lipids, helper lipids, cholesterol, and PEG-modified lipids, with anti-CD4 antibodies anchored to the surface via maleimide-thiol coupling; this invention targets pathogenic CD4... + Specific delivery of T cells and silencing of the Runx3 gene solve the problems of side effects caused by non-specific immunosuppression and insufficient targeting of lipid nanoparticles.

The invention relates to a traditional Chinese medicine composition for treating rhinitis and belongs to the technical field of traditional Chinese medicines. The composition is prepared from traditional Chinese medicinal materials such as centipeda minima, phryma leptostachya, cocklebur fruit, mint, asarum, camphor and the like through gradient crushing to obtain micron-sized powder with D90 smaller than or equal to 150 microns, and is prepared through low-temperature drying, volatile oil directional extraction and honey shaping processes. Aiming at acute and chronic rhinitis, allergic rhinitis, nasosinusitis, nasal polyp and other diseases, the composition provided by the invention realizes simultaneous treatment of principal and subordinate symptoms through anti-inflammatory and detumescence, immunity regulation, mucous membrane repair and other multi-target effects. According to the technology, through component optimization, process innovation and intelligent drug delivery design, the problems that a traditional Chinese medicine preparation is fuzzy in component, low in absorption rate, high in recurrence rate and the like are solved, and a safe, efficient and convenient new choice is provided for rhinitis treatment.

The present invention relates to methods of using compounds of Formula I,wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.

The present invention relates to compositions and methods for the treatment of infection caused by Streptococcus pneumonia. In particular, the invention provides human hyperimmune globulin and compositions thereof for preventing or treating pneumococcal infection. The invention provides methods of producing hyperimmune globulin containing high titers of opsonophagocytic anti-pneumococcal antibodies, compositions containing same, and methods of using the compositions for the prevention and treatment of pneumococcal infection. The invention further provides methods of preventing or treating pneumococcal infection (e.g., upper respiratory infections (e.g., bronchitis, otitis, sinusitis, etc.)) in immunocompromised subjects via administration of hyperimmune globulin compositions of the invention (e.g., containing a high titer of opsonophagocytic anti-pneumococcal antibodies) to immunocompromised subjects.

The present application relates to the technical field of traditional Chinese medicine, and particularly relates to a houttuynia cordata coated nose ointment, a preparation method and application. The houttuynia cordata coated nose ointment comprises the following components in percentage by weight: 5-10% of houttuynia cordata extract, 80-90% of a vaseline-lanolin compound base, 1-3% of a penetration enhancer, and 0.1-0.5% of an antioxidant. The mass ratio of vaseline to lanolin in the vaseline-lanolin compound base is 7:3. The present application uses the houttuynia cordata extract as a core effective component, and is prepared by matching the vaseline-lanolin compound base, the penetration enhancer and the antioxidant in a specific proportion to form an external ointment, which can accurately solve the problems of drug resistance, obvious adverse reactions, poor dosage form adaptability and insufficient targeting in the treatment of existing sinusitis.

The invention provides systems, devices, and methods for alleviating symptoms associated with a condition in a sinonasal cavity of a patient, such as sinonasal inflammatory disease, wherein such symptoms may include nasal congestion, facial pain and pressure, rhinorrhea and post-nasal drip. A neuromodulation device of the present invention includes a wearable or implantable oral appliance having one or more energy delivering elements strategically positioned along a surface thereof for delivery of therapeutic energy. The one or more energy delivering elements are positioned such that, upon the appliance being worn or implanted, the energy delivering elements become aligned with, and able deliver energy to, one or more target sites within the patient's oral cavity to thereby provide targeted stimulation of specific nerves to thereby alleviate symptoms.

To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.

The invention generally relates to systems and methods for targeting of specific tissue(s) of interest within a sino-nasal region of a patient, specifically sinus regions (i.e., ostia and sinus cavities), for the treatment of chronic sinusitis conditions.

To provide methods for getting data to classify patients with chronic sinusitis, to provide kits for classifying patients with chronic sinusitis, to provide arrays for classifying patients with chronic sinusitis, and to provide apparatus for classifying patients with chronic sinusitis.SOLUTION: One embodiment of the present invention uses the expression of at least three genes contained in a gene cluster consisting of a plurality of specific genes as an index.SELECTED DRAWING: None

The application discloses a traditional Chinese medicine atomizing liquid for treating rhinitis and a preparation method and application thereof, and belongs to the field of traditional Chinese medicine, wherein the traditional Chinese medicine atomizing liquid comprises the following raw materials in parts by weight: mace 20-25 parts, clove 45-50 parts, red ginseng 15-20 parts, cardamom 20-25 parts, cardamom 20-25 parts, kadsura 20-25 parts and chuanmuhuang 20-25 parts. The traditional Chinese medicine atomizing liquid can be applied to different types of rhinitis such as acute rhinitis, chronic rhinitis, allergic rhinitis and sinusitis, has obvious relieving effects on symptoms such as nasal congestion, much rhinorrhea, olfactory decline, headache, memory decline and easy tiredness, and the like. In addition, the traditional Chinese medicine atomizing liquid has positive prevention and treatment effects on early rhinitis, and has relieving functions on mature rhinitis, has the characteristics of good curative effect, convenient carrying, less pain, no side effects and the like.

The present invention relates to materials, devices, kits and methods for use in treatment of patients having a sinus condition such as severe chronic rhinosinusitis. The implant configured to fit ins

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the autonomic nervous system. The focused ultrasound signal can have a mechanical index of between about 0.1 to about 5.0 and / or an acoustic pressure of between about 0.1 MPa to about 2.5 MPa. The medical condition can comprise chronic or refractory rhinitis, chronic rhinosinusitis, autonomic instability / autonomic dysfunction, functional gastrointestinal disorders, inflammatory disorders, immune disorders (including improving cancer and infections by neuromodulation of immune function), complex regional pain syndrome, post-traumatic stress disorder (PTSD), anxiety and anxiety-associated disorders, autism, fibromyalgia, uterine function, metabolic disorder, urinary incontinence or binge eating.

The invention relates to specific polyglycerol derivatives and their further medical uses, namely to dPG / lPG-DTBA and dPG / lPG-cysteamine. These polyglycerol derivatives have a linear or dendritic polyglycerol backbone and carry at least one thiol group covalently bound to the polyglycerol backbone. The claimed medical uses are the use as mucolytic; the use in treating chronic sinusitis, asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease, emphysema, or bronchiectasis; and the use in treating chronic inflammatory bowel diseases, constipation, gastrointestinal malabsorption syndrome, irritable bowel syndrome, steatorrhea or diarrhea.

Disclosed herein, in part, are pharmaceutical compositions comprising dupilumab and arginine-glutamate and methods of using the pharmaceutical compositions to treat medical disorders e.g., atopic dermatitis, eosinophilic esophagitis, prurigo nodularis, asthma, or chronic rhinosinusitis in a patient in need thereof.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for preventing and treating or improving nasosinusitis and a preparation method and application thereof. The traditional Chinese medicine composition for preventing and treating or improving nasal-nasosinusitis comprises the following raw materials in parts by weight: 8-10 parts of pogostemon cablin, 3-5 parts of pericarpium citri reticulatae, 8-10 parts of radix angelicae, 13-15 parts of wax gourd kernels, 13-15 parts of poria cocos and 13-15 parts of fried coix seeds. The traditional Chinese medicine composition is based on the concept of tonifying spleen, clearing damp and dredging orifices, and is good in effect of treating or improving nasal sinusitis, safe, reliable, good in taste and easy to accept.